In April 2025, the Eurasian Economic Commission (EEC) adopted two key decisions facilitating the formation of a common market for medical products in the territory of the organisation’s member states.
The Eurasian Economic Commission is a permanent supranational regulatory body of the EAEU, which develops and implements regulations that are binding on all member states. The EAEU consists of Belarus, Kazakhstan, Armenia, Kyrgyzstan and Russia.
On 1 April 2025, the EEC Collegium approved the Concept for the Development of a Common Market for Medical Devices within the EAEU. This document lays the foundation for the formation of unified rules for the circulation of medical devices – from implants and diagnostic equipment to disposable materials. It aims to eliminate disparate approaches to the registration, quality, safety and distribution of such products in different countries of the Union.
In addition, on 8 April, the EEC agreed to extend the transition period for bringing the registration dossiers of medicines in line with the unified requirements of the EAEU. Initially, the period was to end in December 2024, but now companies have been given additional time – until the end of 2027. This extension is intended to ensure a smoother and more controlled transition to the functioning of the common pharmaceutical market, prevent possible disruptions in the supply of vital drugs and enable manufacturers to adapt correctly to the new rules.
VirusOFF hopes that the implementation of the approved concept and the extension of the transitional period for drug registration will create more predictable conditions for manufacturers, open new opportunities for innovation and strengthen confidence in products manufactured in the EAEU countries.